The clinical strategies for reduction of molecular testing further encompass ESGO low-risk cases (e.g., with low grading and no LVSI) and should encounter the existence of multiple classifier carcinomas with combinations of POLE, MMRdef, and p53abn in up to 3% of cases (41). Here, POLE is linked to carcinoma.